Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Journal of Medicinal Chemistry|October 10, 1998
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonistsJ B Thomas, X Zheng, S W Mascarella, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2000
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisM L Tetef, K A Margolin, J H Doroshow, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonistsJ B Thomas, S W Mascarella, J P Burgess, et al.
Journal of Medicinal Chemistry|April 13, 2001
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamidesJ B Thomas, X M Herault, R B Rothman, et al.
Translational Psychiatry|May 13, 2015
Abnormal error processing in depressive states: a translational examination in humans and ratsC Beard, R J Donahue, D G Dillon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2017
Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast CancerJoanne E Mortimer, James R Bading, Jinha M Park, et al.
Journal of Medicinal Chemistry|August 10, 2001
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activityJ B Thomas, R N Atkinson, R B Rothman, et al.
Journal of Medicinal Chemistry|December 19, 1998
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidineJ B Thomas, M J Fall, J B Cooper, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.
British Journal of Cancer|October 29, 2014
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumorsM Koczywas, P H Frankel, T W Synold, et al.
Pageof 21